Source: Pharma Biz
Privo Technologies Inc., a leader in innovative drug delivery and cancer treatment, has launched a new subsidiary, BeneVet Oncology, to improve the health of companion animals. Leveraging Privo’s advanced human medicine technologies, BeneVet aims to address unmet needs in Veterinary care with a focus on safety, efficacy, and ease of administration. Initial research will target cutaneous and subcutaneous solid tumors in pets, using intratumoral injections (PRV131) and topical sustained-release treatments for chronic pain.
BeneVet plans to collaborate with veterinarians, researchers, and pet owners to ensure real-world effectiveness and explore partnerships with animal health organizations. CEO Dr. Manijeh Goldberg emphasized that pets deserve the same innovation as humans, and BeneVet reflects Privo’s mission to extend life-changing therapies to animals. This expansion builds on Privo’s success in human oncology and signifies a major step toward transforming Veterinary medicine with science-driven, practical solutions.
Read the full story HERE: https://www.pharmabiz.com/NewsDetails.aspx?aid=176999&sid=2